Century Therapeutics (IPSC) Accounts Payables (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Accounts Payables data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 11.84% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 11.84% decrease from a year earlier, with the FY2025 full-year figure at $4.8 million, up 55.22% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.2 million, down from $4.8 million in the prior quarter.
• Over the last five years, Accounts Payables for IPSC reached as high as $9.9 million in Q1 2022 and fell as low as $2.6 million in Q3 2024.
• Historically, Accounts Payables has averaged $4.2 million across 5 years, with a median of $3.5 million in 2023.
• Across the five-year window, Accounts Payables sank 69.85% in 2022 and soared 55.22% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $5.5 million in 2022, then tumbled by 49.74% to $2.7 million in 2023, then advanced by 12.19% to $3.1 million in 2024, then surged by 55.22% to $4.8 million in 2025, then slumped by 34.0% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $3.2 million in Q1 2026, $4.8 million in Q4 2025, and $2.6 million in Q3 2025.